Treatment of High Risk MDS: Azacitidine Trials, Immune Checkpoint Inhibitors, Allogeneic Transplant, TP53 Mutations and Iron Chelation Therapy
By
Indy Hematology Review
FEATURING
Richard Stone
By
Indy Hematology Review
FEATURING
Richard Stone
Comments 0
Login to view comments.
Click here to Login
